Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 14/20 | 0.49 |
| ▸ | BRD4 | O60885 | 2/20 | 0.49 |
| ▸ | STAT3 | P40763 | 1/20 | 0.47 |
| ▸ | MAP1LC3B | Q9GZQ8 | 3/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25756277 | 0.91 | CRBN (0.47) | CRBNBRD4STAT3MAP1LC3B | |
| SCHEMBL24068675 | 0.90 | CRBN (0.49) | CRBNBRD4STAT3MAP1LC3BEGFR | |
| SCHEMBL25755862 | 0.89 | STAT3 (0.47) | CRBNBRD4STAT3MAP1LC3BEGFR | |
| SCHEMBL25032251 | 0.88 | STAT3 (0.52) | CRBNBRD4STAT3MAP1LC3BEGFR | |
| SCHEMBL19438825 | 0.87 | CRBN (0.55) | CRBNBRD4STAT3MAP1LC3BHDAC3 | |
| SCHEMBL30577345 | 0.87 | CRBN (0.55) | CRBNBRD4STAT3MAP1LC3BHDAC3 | |
| SCHEMBL20913661 | 0.87 | CRBN (0.55) | CRBNBRD4STAT3MAP1LC3BHDAC3 | |
| SCHEMBL19438857 | 0.87 | CRBN (0.55) | CRBNBRD4STAT3MAP1LC3BHDAC3 | |
| SCHEMBL23765918 | 0.87 | CRBN (0.49) | CRBNBRD4STAT3MAP1LC3BHDAC3 | |
| SCHEMBL23766009 | 0.87 | CRBN (0.49) | CRBNBRD4STAT3MAP1LC3BHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | UCHL3, UBE2L3, ADAM33 | CRBN 286/4885BRD4 1230/4885STAT3 3869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.